SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Elvis Presley

PatientElvis Presley
Date of birth1987-01-08
IdentifiersMRN HR-ML003-SYN; SSN (made up) 000-03-4417
Document date2026-07-17
AuthorColeman Ashby-Nakagawa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

One-week review, seen the same day by addiction medicine. [S]

History of Present Illness

Mr. Presley returns one week after intake and is seen by Dr. Eberhardt-Mensah of addiction medicine on the same day. He has taken only the medicines this clinic prescribed, from one pharmacy, and brought the remaining tablets. As agreed, he took his last hydromorphone about 18 hours ago and his last oxycodone about 20 hours ago so that buprenorphine could be started today; he has yawning, a runny nose, aching legs, gooseflesh and loose stools. He took his usual diazepam and alprazolam last night. His in-laboratory sleep study three days ago showed moderate obstructive sleep apnea. His home blood pressure readings over six days, after stopping phentermine, averaged 146/94. His bowels opened twice this week on polyethylene glycol and senna. He has kept his firearms locked and the naloxone in the house. He says he is ready to start treatment before his engagement. [S]

ElementDetail
Last full-agonist opioidHydromorphone 18 hours ago; oxycodone 20 hours ago
WithdrawalYawning, rhinorrhea, aching, gooseflesh, loose stools; COWS 12 (moderate)
Sleep studyApnea-hypopnea index 26; central apnea index 4; nadir 80%
Home blood pressureAverage 146/94 over six days
BowelsTwice this week

Review of Systems

SystemResultFinding
ConstitutionalPositiveAching and chills from withdrawal
GastrointestinalPositiveLoose stools today; mild cramps
EyesPositiveWatery eyes; no pain or halos
PsychiatricPositiveAnxious about withdrawal; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultationUp to five tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultationUp to three tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a timeOne tablet three times daily; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a timeUp to three tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucomaStoppedOral route2026-07-10 to 2026-07-10completedS
Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologistOne drop in each eye at bedtimeOphthalmic route2026-07-10activeS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bagOne spray for a suspected overdose; call 911Nasal route2026-07-10activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g in water once dailyOral route2026-07-10activeS
Senna 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route2026-07-10 to 2026-08-07completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic onlyTwo films once daily, or one film twice dailySublingual route2026-07-17activeS
Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stableOne tablet four times daily; seven-day supplyOral route2026-07-17 to 2026-08-07completedS
Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-07-17activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-17Body height183cmS
2026-07-17Body weight108.6kgS
2026-07-17Body mass index (BMI) [Ratio]32.4kg/m2S
2026-07-17Systolic blood pressure146mm[Hg]S
2026-07-17Diastolic blood pressure94mm[Hg]S
2026-07-17Heart rate102/minS
2026-07-17Respiratory rate18/minS
2026-07-17Body temperature37CelS
2026-07-17Oxygen saturation in Arterial blood by Pulse oximetry96%S

Physical Exam

Vital signs recorded on 2026-07-17; see the Vital Signs section. [S]

SystemFinding
GeneralRestless, yawning; blood pressure 146/94, pulse 102, temperature 37.0 °C
EyesPupils 5 mm and reactive; lacrimation
SkinPiloerection; sweating; no injection marks
NeurologicalMild tremor of the outstretched hands; alert and oriented

Problems

ProblemClinical statusVerificationCodeProvenance
Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readingsresolvedconfirmed R53.83S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses.
Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped workingactiveconfirmed E66.811S — Synthetic modern diagnosis anchored to his documented weight gain.
Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoidedactiveconfirmed H40.63X1S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes.
Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillersactiveconfirmed F11.20S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis.
Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedativesactiveconfirmed F13.20S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis.
Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normalactiveconfirmed I10S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension.
Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAPactiveconfirmed G47.33S — Synthetic modern diagnosis from a synthetic sleep study.
Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm featuresactiveconfirmed K59.03S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, withdrawal symptoms, cravings and other opioid useEvery visit; weekly contact in the first monthCompleted todayCOWS 12 before the first dose; 8 mg given in the office; 16 mg a day from tomorrow
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's seven-day prescriptions since intake; the earlier prescribers notified that this clinic now prescribes
LaboratoryUrine drug test, including buprenorphine metabolite and fentanylAt the start of treatment, then about monthly while doses are changingCompleted todayPoint-of-care test today: hydromorphone, oxycodone and benzodiazepines present; fentanyl and other drugs absent (narrative)
Medication safetyNaloxone on hand and people taught to use itEvery visitCompleted todayTwo-pack at home and one in the tour bag; two friends trained
Medication safetyDiazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper paceEvery two to four weeks during the taperCompleted todayDiazepam 30 mg and alprazolam 3 mg a day combined into diazepam 40 mg a day; no taper step during the buprenorphine start
SurveySuicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; firearms locked; medicines in a locked box; 988 in his phone
SurveyMood (PHQ-9) and anxiety (GAD-7)At baseline, four to six weeks after a change in treatment, then at each reviewUp to datePHQ-9 8 and GAD-7 9 at intake; repeat at the next visit
ExaminationOffice and home blood pressure (target below 130/80)Every visitCompleted todayOffice 146/94 in withdrawal; home average 146/94; treatment started
ImagingElectrocardiogram at diagnosis of hypertensionAt diagnosisUp to dateNormal at intake, QTc 436 ms
LaboratoryPotassium and creatinine after starting an angiotensin receptor blockerTwo to four weeks after starting, then every six monthsDueValsartan started today; check at the next visit
ExaminationWeight and BMIEvery visitCompleted today108.6 kg, BMI 32.4
SurveyCPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)Within the first 30 to 90 days, then at each reviewDuePolysomnogram three days ago; CPAP starts this week
Self-managementBowel frequency, straining and alarm featuresEvery visitCompleted todayTwice this week; no blood, weight loss or vomiting
ExaminationGlaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-upEvery visit; ophthalmology every three to six months while recently controlledCompleted todayLatanoprost nightly; phentermine and the nonprescription diphenhydramine sleep aid stopped; no eye pain or halos; ophthalmology visit in September
ReferralAddiction medicine consultationAt diagnosisCompleted todaySeen by Dr. Eberhardt-Mensah today
Self-managementTouring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagementBefore each engagement or tourUp to dateLas Vegas engagement in five weeks; plan to be written at the next visit

Goal progress:

Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019); American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Phone check tomorrow and weekly contact. Three-week review. Call or use naloxone and 911 for heavy sedation or slow breathing. Next scheduled visit 2026-08-07: three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement. [S]